The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...